ABSTRACT Background: Published associations between dietary carotenoids and vitamin C and bladder cancer risk are inconsistent. Biomarkers may provide more accurate measures of nutrient status. Objective: We investigated the association between plasma carotenoids and vitamin C and risk of urothelial cell carcinoma (UCC) in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition. Design: A total of 856 patients with newly diagnosed UCC were matched with 856 cohort members by sex, age at baseline, study center, date and time of blood collection, and fasting status. Plasma carotenoids (a-and b-carotene, b-cryptoxanthin, lycopene, lutein, and zeaxanthin) were measured by using reverse-phase HPLC, and plasma vitamin C was measured by using a colorimetric assay. Incidence rate ratios (IRRs) were estimated by using conditional logistic regression with adjustment for smoking status, duration, and intensity. Results: UCC risk decreased with higher concentrations of the sum of plasma carotenoids (IRR for the highest compared with the lowest quartile: 0.64; 95% CI: 0.44, 0.93; P-trend = 0.04). Plasma b-carotene was inversely associated with aggressive UCC (IRR: 0.51; 95% CI: 0.30, 0.88; P-trend = 0.02). Plasma lutein was inversely associated with risk of nonaggressive UCC (IRR: 0.56; 95% CI: 0.32, 0.98; P-trend = 0.05). No association was observed between plasma vitamin C and risk of UCC. Conclusions: Although residual confounding by smoking or other factors cannot be excluded, higher concentrations of plasma carotenoids may reduce risk of UCC, in particular aggressive UCC. Plasma lutein may reduce risk of nonaggressive UCC.
INTRODUCTION
During the past decades, there has been considerable interest in the role of antioxidants in the prevention of cancer. Carotenoids and vitamin C received much attention, particularly because they may prevent DNA damage by neutralizing free radicals and oxidants (1) .
Dietary intake of carotenoids and vitamin C may reduce risk of bladder cancer (2) . However, results from prospective studies are inconsistent. This inconsistency may partly be due to misclassification of self-reported vegetable and fruit consumption, which is the primary source of dietary carotenoids and vitamin C (3) . Only a few studies used circulating blood concentrations of carotenoids or vitamin C, which reflect both dietary and supplemental intakes (4) (5) (6) (7) . A case-control study (4) in the United States and a nested case-control study (5) in Japanese-American men showed inverse associations between bladder cancer risk and several individual carotenoid concentrations. Two prospective studies showed no association between circulating carotenoids and bladder cancer risk (6, 7) .
Contradictory results may also be explained because urothelial cell carcinoma (UCC) 6 of the bladder is often considered to be one disease although it represents a heterogeneous group of tumors with different prognoses that develop through different molecular pathways. Low-grade papillary tumors are characterized by activating mutations in the HRAS and FGFR3 oncogenes and chromosome 9 aberrations; high-grade papillary and solid tumors are characterized by structural and functional defects in the TP53 and RB tumor-suppressor genes (8, 9) .
We examined the association between prediagnostic plasma carotenoids and vitamin C concentrations and risk of prognostic subgroups of UCC in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC).
SUBJECTS AND METHODS

Study population and data collection
The design and methods of the EPIC study have been previously described in detail (10, 11) . Briefly, the EPIC is a cohort study comprising more than one-half million people recruited in 23 centers in 10 European countries (Denmark, France, Germany, Greece, Italy, Netherlands, Norway, Spain, Sweden, and the United Kingdom). Study participants were aged between 25 and 70 y and were recruited between 1992 and 2000, mainly from the general population. Eligible subjects were invited to participate in the study, and subjects who consented completed standardized questionnaires on their diet, lifestyle, and medical history at enrollment (10) (11) (12) . Usual dietary intake during the year before recruitment was measured by using country-specific validated diet questionnaires designed to reflect local dietary patterns (10, 11) . Intakes of dietary b-carotene (the only dietary carotenoid currently available in the EPIC database) and vitamin C were estimated by using standardized country-specific food composition tables (12) . Data on the use of dietary supplements (yes compared with no) were collected for w80% of the cohort.
In each of the participating centers, blood samples of $20 mL were drawn at baseline from consenting participants (74% of all respondents donated samples). Study centers collected and stored blood samples according to a standardized protocol (10) . After blood donation, samples were stored at 5-10 8 C, protected from light, and transported to local laboratories for processing and dividing into aliquots. Exceptions were the EPIC-Oxford (United Kingdom) and EPIC-Norway centers, where blood samples were collected from a network of general practitioners and transported to a central laboratory by post, and centers in Sweden, where blood was divided into aliquots #1 h after collection. In all countries, except in Denmark and Sweden, blood was separated into 0.5-mL fractions (serum, plasma, red cells, and buffy coat for DNA extraction) and stored in heatsealed straws in liquid nitrogen (2196 8 C). One-half of all aliquots were stored at the local study center and the other one-half of aliquots were stored in the central EPIC biorepository at the International Agency for Research on Cancer (IARC, Lyon, France). In Denmark, blood-fraction aliquots in 1-mL tubes were stored at 2150 8 C under nitrogen vapor. In Sweden, samples were stored in 1.8-mL tubes in 280 8 C freezers (10, 11). All participants gave written informed consent, and the study was approved by the Institutional Review Board of IARC and the local ethics committees in participating countries.
Nested case-control design and selection of participants Incident cancer cases were identified through linkage to population-based cancer registries in Denmark, Italy (except Naples), the Netherlands, Norway, Spain, Sweden, and the United Kingdom or through a combination of methods including linkage to health insurance records, cancer and pathology registries, and active follow-up of study participants or their next of kin in France, Germany, Greece, and Naples (Italy were censored at the end of follow-up, last known contact, cancer diagnosis, or death. Participants were followed from study entry until a first primary bladder cancer diagnosis (code C67 according to the International Classification of Diseases-Oncology, third edition, 2000), death, emigration, or end of the follow-up period. Only urothelial cell papillomas and carcinomas (morphology codes 8120 and 8130) were included in the analyses. Pathology reports of UCC cases were collected from each center. Stage T1 and higher, carcinoma in situ, or WHO grade 3 carcinomas were classified as aggressive UCCs, whereas stage Ta grades 1 or 2 were classified as nonaggressive UCCs (13) . Ninety-two percent of the cases were classified as aggressive or nonaggressive UCC.
Each case was matched to one control subject by incidence density sampling from all cohort members alive and free of cancer at the time of diagnosis of cases (except for nonmelanoma skin cancer). Controls were randomly selected from the population at risk at the time of the index case occurrence. Under this design, a selected control could have served as a control for another case and may have become a case at a later time in follow-up. Matching criteria were sex, age at time of enrollment (63 y), study center, date of blood collection (63 mo), time of day of blood collection (62 h), and fasting status at the time of blood collection (,3, 3-6, and .6 h since last meal). Matched controls were unavailable for 11 cases, and these individuals were excluded from analyses. The current study included 856 pairs of first primary UCC cases and their matched controls.
Laboratory assays
Aliquots of plasma were extracted from the central biorepository at IARC and the local centers of Denmark and Sweden. The frozen plasma was shipped in dry ice to the National Institute for Public Health and the Environment (Bilthoven, Netherlands) for analysis. Samples were thawed shortly before analysis. Seven carotenoids (a-and b-carotene, b-cryptoxanthin, lycopene, lutein, zeaxanthin, and cantaxanthin) were simultaneously analyzed with HPLC by using an HPLC column (250 3 4.6 mm, ChromSpher 5-mm C18; Varian Association) with detection at 450 nm. Echinenone was used as internal standard (14) . Cantaxanthin concentrations were close or below the limit of detection for most samples and, therefore, were not used in the current study. Approximately 4.5% of concentrations of the other carotenoids were under the limit of detection (20 nmol/L) and were set at the detection limit. For quality control, one control sample with concentrations similar to mean concentrations in controls was added to each batch of samples to assess interbatch reproducibility. There were 25 batches. CVs for these quality-control samples were 14.6% for a-carotene, 6.3% for b-carotene, 4.4% for b-cryptoxanthin, 10.1% for lycopene, 7.8% for lutein, and 10.5% for zeaxanthin. Plasma vitamin C concentrations were determined with an LX20-Pro autoanalyzer (Beckman-Coulter) by using a colorimetric assay (15) . The CV for vitamin C was 4.7% at a vitamin C concentration of 28.3 mmol/L. The limit of sensitivity of the method was 2.5 mmol/L, and no peaks of vitamin C were under the limit of detection. To minimize the influence of batch-to-batch variation, cases were analyzed in the same analytic batch as their matched controls. Laboratory technicians were blinded to the case-control status of samples, and biochemical analyses were done in one laboratory, with avoidance of between-laboratory method variability. Plasma carotenoids and vitamin C have been estimated to be stable for several years at different storage temperatures (16, 17) .
Statistical analysis
ORs and 95% CIs for UCC risk in relation to plasma concentrations and dietary intakes were calculated by using conditional logistic regression models stratified by the case-control set. With an incidence density sampling design, the OR is an unbiased approximation of the incidence rate ratio (IRR) (18) . IRRs were calculated by using quartiles with cutoffs that were based on the distribution of carotenoids and vitamin C in control subjects. We derived probability values for a linear trend across quartiles from regression models by using median plasma concentrations within quartiles as a continuous variable, thereby taking the unequal distances of the quartiles into account (19) . The data were also analyzed as continuous variables. Plasma values of carotenoids and vitamin C were log 2 -transformed to improve normality. The IRR of these log 2 -transformed variables corresponded to the reduction of UCC risk with the doubling of the plasma concentration or dietary intake.
All analyses were controlled for smoking status (never, former, or current), duration of smoking (years), and lifetime intensity of smoking (cigarettes/d). Energy intake (continuous), consumption of processed or red meat (continuous), alcohol intake (continuous), physical activity (inactive, moderately inactive, moderately active, or active), BMI (continuous), occupational history, and educational level (primary school or less, technical-professional school, secondary school, or university) were not included in the final analyses because none of these factors noticeably affected the b estimates of plasma variables. Additional analyses were performed by using nonaggressive and aggressive UCCs as separate endpoints.
Because smoking could have modified the investigated associations, joint effects were determined for tertiles of plasma carotenoids and vitamin C in combination with smoking status (never, former, or current) in relation to UCC risk. The combined category of low plasma carotenoids or vitamin C with current smoking was chosen as reference. We used tertiles of plasma carotenoids or vitamin C instead of quartiles to have enough power. The statistical interaction on a multiplicative scale was tested by introducing a product term between plasma carotenoids or vitamin C (continuous) and smoking status. Analyses of joint effects were controlled for duration of smoking (y) and lifetime intensity of smoking (cigarettes/d). Similar models were used to test for interactions with sex, alcohol intake, and BMI. To evaluate whether preclinical disease may have influenced results, analyses were repeated after exclusion of cases along with their matched controls who were diagnosed within 2 y after recruitment (n = 134 pairs).
All statistical analyses were performed with SAS software (version 9.2; SAS Institute Inc). For all analyses, 2-sided P , 0.05 was considered statistically significant.
RESULTS
As expected, UCC cases were more likely to smoke. They were also slightly less educated, reported a higher intake of alcohol, and consumed less fruit and vegetables. Of 856 UCC cases, 405 cases were classified as aggressive and 384 cases were Table 1) . No significant associations were observed between concentrations of individual carotenoids, vitamin C, and risk of total UCC. The sum of carotenoids, however, showed an inverse association with total UCC (IRR for highest compared with lowest quartile: 0.64; 95% CI: 0.44, 0.93; P-trend = 0.04). For the sum of carotenoids, inverse associations were quite similar for aggressive and nonaggressive UCC risk, but the reduction in risk of aggressive UCC was only significant for subjects in the highest quartile (IRR for highest compared with lowest quartile: 0.53; 95% CI: 0.30, 0.94; P-trend = 0.05) ( Table 2) . Plasma b-carotene was inversely associated with aggressive UCC (IRR for highest compared with lowest quartile: 0.51; 95% CI: 0.30, 0.88; P-trend = 0.02) but not with nonaggressive UCC. For nonaggressive UCC, inverse associations were observed for plasma lutein (IRR highest compared with lowest quartile: 0.56; 95% CI: 0.32, 0.98; P-trend = 0.05) ( Table 2 ). These inverse associations persisted after exclusion of cases diagnosed during the first 2 y of follow-up (data not shown).
For dietary b-carotene, an inverse association was observed with total UCC risk (IRR for highest compared with lowest quartile: 0.70; 95% CI: 0.50, 0.97; P-trend = 0.04). A higher intake of dietary b-carotene was borderline significantly inversely associated with nonaggressive UCC risk (IRR for higher compared with lowest quartile: 0.61; 95% CI: 0.37, 0.99; Ptrend = 0.09) but not with aggressive UCC risk ( Table 3) . In contrast, for plasma b-carotene, an inverse association was shown for aggressive UCC but not for nonaggressive UCC (Table 2) . A higher intake of dietary vitamin C was not associated with UCC risk (Table 3) .
When joint effects of smoking status and plasma carotenoids and vitamin C were evaluated, smoking was the dominant risk factor. Although the interaction of smoking status and plasma carotenoids was not significant (P-interaction = 0.27), compared with the reference category (current smokers in the lowest tertile of plasma carotenoids), the lowest UCC risk was seen in current smokers with increasing plasma concentrations of carotenoids (IRR for highest compared with lowest plasma carotenoid concentrations: 0.61; 95% CI: 0.38, 0.99) ( Table 4) . In comparison with the reference category (current smokers in the lowest tertile of plasma vitamin C), a graded decrease in UCC risk with increasing plasma concentrations of vitamin C was shown in current smokers (IRR for highest compared with lowest plasma vitamin C concentrations: 0.63; 95% CI: 0.41, 0.97; P-interaction = 0.007) ( Table 4 ). These data suggest that smoking may modify the association between plasma carotenoids and vitamin C and risk of UCC. The associations between plasma carotenoids or vitamin C and risk of UCC were not modified by sex, alcohol intake, or BMI (data not shown).
DISCUSSION
In the current study, the sum of plasma carotenoids was inversely associated with UCC risk. Inverse associations were also observed for b-carotene and risk of aggressive UCC and between plasma lutein and risk of nonaggressive UCC. No association was observed between plasma vitamin C concentrations and UCC risk. Risk of UCC was reduced with increasing plasma concentrations of vitamin C in current smokers.
The relation between circulating carotenoids and bladder cancer risk has been previously investigated. A case-control study (4) that included 84 cases showed that plasma lutein, a-carotene, b-cryptoxanthin, and lycopene were inversely associated with bladder cancer risk. However, results may have been biased by changes in blood concentrations after diagnosis. A nested casecontrol study of Japanese-American men with 111 incident cases of bladder cancer showed inverse associations between serum a-carotene and lutein plus zeaxanthin (5) . Two other prospective studies observed no associations between b-carotene (6, 7) and lycopene (7) and bladder cancer risk. These studies also had a very small sample size (10-20 cases) and may have lacked power to detect any significant difference in risk. Randomized intervention trials that involved synthetic b-carotene (20) (21) (22) or vitamin C (23) supplements and examined bladder cancer as a secondary endpoint showed increased risks (20) as well as no associations (21-23). The null or harmful effect of b-carotene on bladder cancer risk in trials is inconsistent with the inverse association seen in our cohort. Although observational studies observe the effect of b-carotene in the general population, clinical trials can examine only a specific intervention, in a specific population, over a relatively short period of time. Also much higher doses of b-carotene were used than obtained from the diet. Despite the inconsistencies among trials, it is unlikely that the different pharmacologic doses of b-carotene that were used would prevent bladder cancer.
In our study, dietary b-carotene was borderline significantly inversely associated with UCC risk, whereas dietary vitamin C was not associated with UCC risk. The correlation coefficient between plasma concentrations and dietary intake was only 0.20 for b-carotene and 0.16 for vitamin C. These weak correlations may be explained by errors in the food-composition table from 3 Values were derived from adjusted models as described in footnote 2 for risk associated with a doubling in dietary intake.
which dietary b-carotene and vitamin C were derived and biases in the assessment of dietary intake. Other explanations may be related to the bioavailability of carotenoids and vitamin C that can vary substantially depending on the cooking method used or the metabolism of carotenoids and vitamin C that can affect their blood concentrations or because only a single plasma measurement was available. However, risk estimates of plasma concentrations and dietary intakes of b-carotene and vitamin C were quite similar despite the low correlations.
After separation of prognostic risk groups, our findings suggest an inverse association between plasma b-carotene and risk of aggressive UCC. For nonaggressive UCC, inverse associations were observed for plasma lutein. To our knowledge, only 2 previous studies evaluated the effect of carotenoids stratified by bladder tumor aggressiveness. The Alpha-Tocopherol BetaCarotene Prevention trial on b-carotene supplementation observed no difference in risk estimates for invasive and noninvasive bladder tumors (22) . The Netherlands Cohort Study reported that the inverse association between dietary intakes of b-cryptoxanthin did not differ according to bladder tumor aggressiveness (24) . Although antioxidant properties of carotenoids have been suggested as the main mechanism that underlies their inverse association with epithelial cancers (25) , additional mechanisms have also been proposed. a-and b-Carotene and b-cryptoxanthin can be converted into vitamin A, which is involved in cell differentiation and enhancement of the immunologic response. In addition, carotenoids stimulate gap junctional intercellular communication correlated with the growth inhibition of chemically transformed cells (26) . Stivala et al (27) showed that b-carotene induces a cell-cycle delay in the G1 phase in normal human fibroblasts. Aggressive, high-grade bladder tumors are characterized by defects in the RB tumor-suppressor gene, which prevents premature G1/S cell-cycle transition. This potential mechanism suggests that b-carotene can modulate aggressive bladder carcinogenesis through pathways related to cancer cell proliferation.
In the current study, plasma vitamin C or carotenoid concentrations in combination with smoking status suggest that there is a graded decrease in UCC risk in current smokers with a high concentration of plasma vitamin C or carotenoids. Thus, if an effect of plasma vitamin C or carotenoids exists, our study suggests that it is more prominent in current smokers. This finding is in line with the hypothesis that smokers may benefit more from vitamin C or carotenoids intake than nonsmokers. The high antioxidant content of vitamin C or carotenoids may reduce the oxidative damage caused by cigarette smoking (28) . However, the inverse associations observed should be interpreted with caution because we conducted multiple comparisons, and residual confounding by smoking could not be excluded.
Our results showed that the inverse associations remained unchanged when the results were adjusted for several lifestyle factors. However, inverse associations seen in observational studies may reflect other unmeasured lifestyle factors associated with both high plasma concentrations of carotenoids and low risk of bladder cancer. Thus, high plasma concentrations of carotenoids may just be a marker of a healthy lifestyle (29) . In our study, participants with higher plasma concentrations of carotenoids tended to have a healthier lifestyle (data not shown). Higher concentrations of carotenoids may also be a marker of a concerted effect of multiple bioactive compounds in fruit and vegetables. The possibility was not supported by results from Büchner et al (30, 31) who showed no effect of quantity (30) or variety (31) in fruit and vegetable consumption on bladder cancer risk in the EPIC. However, the correlation between plasma markers and the variety of fruit and vegetable consumption was rather weak (data not shown), which makes interpretation difficult.
The strengths of our study included its prospective design, the relatively large number of UCC cases, the wide range in plasma concentrations, and the collection of blood samples before cancer diagnosis. However, there were limitations in this study. Carotenoids are transported in blood as part of lipoprotein complexes, and plasma concentrations may depend on the type and amount of fat consumed. Optimally, plasma concentrations of carotenoids should be adjusted for blood lipids. Still, adjustment for plasma lipids measured in another EPIC study on gastric cancer that used the same biomarkers did not result in any appreciable changes in risk estimates (32) . The use of supplements such as b-carotene or vitamin C could also affect plasma concentrations. In our study, no substantial change in risk estimates was observed by simple adjustment for dietary supplement use (yes compared with no). Unfortunately, information about the type of supplement and frequency of use was not available in our study.
Our analyses were based on single measurements of plasma carotenoids and vitamin C concentrations. On this basis, we assumed that plasma concentrations were stable in persons during follow-up. Blood concentrations may differ over time because of day-to-day variation and long-term changes within persons, which may lead to an attenuation of associations. The repeatability of serum carotenoids has been previously been determined, and intraclass correlation coefficients over 1-4 y ranged from 0.5 to 0.7 (33) . This result suggests a moderate repeatability of measurements of plasma carotenoids and vitamin C. These measures should be reliable enough to detect moderate associations.
In conclusion, this study provides some evidence for a protective role of plasma carotenoids in UCC development. Our results suggest that plasma b-carotene may be protective for aggressive UCC, whereas plasma lutein may be protective for nonaggressive UCC. Residual confounding by smoking or other factors cannot entirely be excluded, and confirmation of our results in other prospective settings is warranted.
